1189988-36-0
1189988-36-0
Chemical Structure
Dasatinib N-oxide-d8
- CAS No.: 1189988-36-0
- Formula:C22H18D8ClN7O3S
- Molecular Weight:512.05
IUPAC Name: 4-(6-((5-((2-chloro-6-methylphenyl)carbamoyl)thiazol-2-yl)amino)-2-methylpyrimidin-4-yl)-1-(2-hydroxyethyl)piperazine 1-oxide-2,2,3,3,5,5,6,6-d8
InChIKey: UEFNEEZCTQCRAW-COMRDEPKSA-N
SMILES: OCC[N+]1([O-])C([2H])([2H])C([2H])([2H])N(C2=NC(C)=NC(NC3=NC=C(C(NC4=C(C)C=CC=C4Cl)=O)S3)=C2)C([2H])([2H])C1([2H])[2H]
Biological Activity: Dasatinib N-oxide-d8 is the deuterium labeled Dasatinib N-oxide. Dasatinib N-oxide is a minor metabolite of Dasatinib. Dasatinib is a potent and orally active dual Src/Bcr-Abl inhibitor[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Dasatinib N-oxide-d8 | Dasatinib N-oxide-d8 is the deuterium labeled Dasatinib N-oxide. Dasatinib N-oxide is a minor metabolite of Dasatinib. Dasatinib is a potent and orally active dual Src/Bcr-Abl inhibitor. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Dasatinib N-oxide (Standard) | ≥98% | L-Ascorbic acid (GMP Like) (Standard) is the analytical standard of L-Ascorbic acid (GMP Like). This product is intended for research and analytical applications. L-Ascorbic acid (GMP Like) is the GMP Like class L-Ascorbic acid (HY-B0166). L-Ascorbic acid (L-Ascorbate, Vitamin C), an electron donor, is an endogenous antioxidant agent. L-Ascorbic acid inhibits selectively Cav3.2 channels with an IC50 of 6.5 μM. L-Ascorbic acid is also a collagen deposition enhancer and an elastogenesis inhibitor. L-Ascorbic acid exhibits anti-cancer effects through the generation of reactive oxygen species (ROS) and selective damage to cancer cells. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Dasatinib N-oxide | 99.24% | Dasatinib N-oxide is a minor metabolite of Dasatinib. Dasatinib is a potent and orally active dual Src/Bcr-Abl inhibitor. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
- [2]. Christopher LJ, et, al. Metabolism and disposition of dasatinib after oral administration to humans. Drug Metab Dispos. 2008 Jul;36(7):1357-64. [Content Brief]
